Humana Inc. filings document formal disclosures for a public healthcare company with Humana insurance services and CenterWell healthcare services. Recent 8-K reports cover quarterly results, GAAP and non-GAAP earnings measures, Insurance segment benefit ratio commentary, Medicare Advantage membership assumptions, Regulation FD communications, and guidance updates.
Humana's SEC records also include proxy and annual-meeting materials covering director elections, auditor ratification, stockholder voting results, board composition, and director compensation program disclosures; board and executive transition disclosures; and capital-structure filings for registered debt offerings, including junior subordinated notes described through Form S-3 and prospectus-supplement materials.
Humana Inc. Chief Information Officer Japan Mehta reported an equity award exercise and related tax withholding. On 2/13/26, Mehta acquired 1,682 shares of Humana common stock through an exercise or conversion of a derivative security at a stated price of $0.0000 per share.
On the same date, 430 shares of Humana common stock were disposed of to cover tax liabilities for shares vesting on 2/13/26, with no value received in return, at a price of $181.4575 per share. Following these transactions, Mehta directly owned 7,728 shares of Humana common stock, which includes 5,752 restricted stock units representing a contingent right to receive one share each.
Humana Inc. Chief Financial Officer Celeste Mellet exercised 7,763 derivative securities into Humana common stock and then used 4,204 shares to satisfy tax withholding for shares vesting on 2/13/26, receiving no value in return. After these transactions, she directly holds 24,250 shares, including 19,785 restricted stock units.
Humana Inc. reported that President, Medicare Advantage Aaron Martin acquired 17,031 shares of Humana common stock on 02/12/2026 through a grant of restricted stock units at a price of $0 per share. These 17,031 restricted stock units each represent a contingent right to receive one share of Humana common stock under the company’s 2019 Amended & Restated Plan.
Humana Inc. reported a 4Q25 net loss per share of ($6.61) on a GAAP basis and ($3.96) on an Adjusted basis, reflecting higher medical costs and impairment charges. For FY 2025, GAAP EPS was $9.84 and Adjusted EPS was $17.14, with Adjusted results in line with management expectations. Consolidated FY 2025 revenues reached $129.7 billion on an Adjusted basis, driven by higher Medicare and state-based premiums and growth in state-based contracts and stand-alone PDP membership, partly offset by exiting unprofitable Medicare Advantage plans. The Insurance segment posted a FY 2025 GAAP benefit ratio of 90.4% and an operating cost ratio of 9.1%, while CenterWell revenues grew to $22.5 billion with stable income from operations.
For FY 2026, Humana issued earnings guidance of at least $8.89 GAAP EPS and at least $9.00 Adjusted EPS, a decline from 2025 tied to the Medicare Star Ratings headwind for Bonus Year 2026, net of mitigation. The company expects approximately 25% growth in individual Medicare Advantage membership over 2025 and projects total 2026 consolidated revenues of at least $160 billion, including at least $155 billion in the Insurance segment and at least $25 billion at CenterWell. Management highlights continued expansion in CenterWell Senior Primary Care, with 100,600 additional patients in 2025, and an expanded Medicaid footprint across 13 states, as key strategic growth drivers.
Humana Inc. executive Aaron Martin, President of Medicare Advantage, filed an initial insider ownership report as of 01/26/2026. The filing shows he beneficially owns 0 shares of Humana common stock, held directly. No derivative securities such as options or warrants are listed as beneficially owned. This is an administrative disclosure of his current holdings as a company officer.
Humana Inc. President & CEO James A. Rechtin reported routine equity award activity on January 8, 2026. A total of 2,183 restricted stock units converted into the same number of Humana common shares at $0 per share under the company’s 2019 Amended & Restated Stock Incentive Plan.
Of these shares, 980 Humana common shares were withheld at a price of $279.1475 per share to satisfy tax obligations related to vesting, with no value received in return. Following these transactions, 28,305 Humana common shares were beneficially owned indirectly through two revocable trusts for the benefit of Rechtin and his spouse, where they serve as sole trustees.
Rechtin also holds stock options covering 29,230 Humana shares at an exercise price of $458.185 and options covering 15,772 shares at $367.21, as well as 14,054 restricted stock units, all granted under the same incentive plan with multi-year vesting schedules.
Humana Inc. director David T. Feinberg reported equity transactions in company stock and stock units. On 01/02/2026, he acquired 766 shares of Humana common stock at a reported price of $0, increasing his directly held beneficial ownership to 1,207 shares.
The filing also details changes in his deferred restricted stock units (RSUs). An existing block of 1,593 RSUs remains outstanding, each representing the right to receive one share of Humana common stock. On 12/31/2025, he elected to convert a director cash fee into 70 stock units and reinvest a dividend into 29 stock units, both deferred and valued at $258.8675 per unit, bringing their respective RSU balances to 708 and 46 units. All units are payable in Humana common stock on a 1-for-1 basis under the company’s equity plan and are reported as exempt under Rule 16b-3.
Humana Inc. director Wayne A. I. Frederick reported equity transactions in Humana common stock. The filing shows a disposition of 440 shares of Humana common stock in Table I.
In Table II, he acquired 766 restricted stock units on 01/02/2026 and 35 restricted stock units on 12/31/2025, each tied to Humana common stock. Following these transactions, he directly beneficially owned 3,174 restricted stock units from the first line and 73 from the second.
According to the footnotes, the larger grant represents an annual director’s fee payable in stock units under Humana’s 2019 Amended & Restated Plan, while the smaller amount reflects dividends reinvested into stock units. Both types of units are deferred until he resigns as a director, when they will be settled in Humana common stock on a one-for-one basis.
Humana Inc. director John W. Garratt reported equity awards and his updated holdings. On 12/31/2025, he acquired 16 restricted stock units tied to dividend payments, and on 01/02/2026 he acquired 766 restricted stock units as part of his annual director fee. These stock units are deferred until he resigns as a director, when they will be settled in Humana common stock on a 1-for-1 basis under the company’s 2019 Amended & Restated Plan.
Following these transactions, he directly beneficially owns 1,685 shares of Humana common stock. He also beneficially owns 1,929 restricted stock units described in note (1) and 18 restricted stock units described in note (2) as derivative securities, each corresponding to one share of Humana common stock upon settlement.
Humana Inc. director reports equity transactions and updated holdings. Director Marcy S. Klevorn reported activity in Humana common stock and related stock units. The filing shows a disposition of 436 shares of Humana common stock in the non-derivative section. In the derivative section, she acquired 766 restricted stock units as part of her annual director’s fee, which is payable in stock units deferred until her resignation, and 28 additional stock units from a director’s dividend payment reinvested at a price of $258.8675 per unit. Following these transactions, she beneficially owns 2,771 restricted stock units tied to Humana common stock under one award and 53 units under the dividend reinvestment award, each representing a contingent right to receive one share of Humana common stock on a 1-for-1 basis.